# US 2026/0023085 A1 · Compositions and methods for analysis, detection, and treatment of multiple sclerosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0023085 A1
- Document ID: US20260023085A1
- Status: Published application
- Kind: A1
- Application number: 18/843,758
- Filed: 2023-03-14
- Published: 2026-01-22
- Earliest claimed: 2022-03-14
- Assignees: The Regents of the University of Michigan
- Applicants: The Regents of the University of Michigan
- Inventors: Qi Wu; Yang Mao-Draayer
- Web page: https://patentgrep.com/patent/US20260023085A1

## CPC

- G01N 33/6863: {Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors}
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- G01N 2333/485: Epidermal growth factor [EGF] (urogastrone)
- G01N 2333/523: Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
- G01N 2333/5255: Lymphotoxin [LT]
- G01N 2333/5434: IL-12
- G01N 2333/5437: IL-13
- G01N 2333/57: IFN-gamma
- G01N 2333/70575: NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154
- G01N 2333/70578: NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
- G01N 2800/285: Demyelinating diseases; Multipel sclerosis
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure relates to materials and methods for prognostic classification of multiple sclerosis patients. In particular, provided herein are biomarkers and methods of uses thereof for stratifying patients with multiple sclerosis. The methods described herein facilitate selection of an appropriate treatment for a subject.

## Claims

### Claim at position 1

-52. (canceled)

### Claim 53

A method comprising measuring protein expression levels of at least 6 proteins in a sample obtained from a subject having or suspected of having multiple sclerosis, wherein the at least 6 proteins are selected from soluble CD40L (sCD40L), Monocyte Chemoattractant Protein-1 (MCP-1), gamma interferon (IFNγ) epidermal growth factor (EGF), neurofilament light chain (NFL), fractalkine/CX3CL1, interleukin-13 (IL-13), Eotaxin, lymphotoxin-alpha (TNFβ/LTα), and interleukin-12 subunit p40 (IL-12p40).

### Claim 54 (depends on 53)

The method of claim 53, wherein the at least 6 proteins comprise at least one of sCD40L, MCP-1, IFNγ, and NFL.

### Claim 55 (depends on 53)

The method of claim 53, wherein the at least 6 proteins comprise at least two of sCD40L, MCP-1, IFNγ, and NFL.

### Claim 56 (depends on 53)

The method of claim 53, wherein the at least 6 proteins comprise at least three of sCD40L, MCP-1, IFNγ, and NFL.

### Claim 57 (depends on 53)

The method of claim 53, wherein the at least 6 proteins comprise each of sCD40L, MCP-1, IFNγ, and NFL.

### Claim 58 (depends on 53)

The method of claim 53, comprising measuring protein expression levels of at least 7 proteins in the sample.

### Claim 59 (depends on 53)

The method of claim 53, comprising measuring protein expression levels of at least 8 proteins in the sample.

### Claim 60 (depends on 53)

The method of claim 53, comprising measuring protein expression levels of at least 9 proteins in the sample.

### Claim 61 (depends on 53)

The method of claim 53, wherein the protein expression levels are measured by an immunoassay.

### Claim 62 (depends on 53)

The method of claim 53, wherein the sample is a plasma sample.

### Claim 63 (depends on 53)

The method of claim 53, further comprising:
a) identifying the subject as having relapsing-remitting multiple sclerosis based on the protein expression levels of the at least 6 proteins, and treating the subject identified as having relapsing-remitting multiple sclerosis with a disease modifying therapy; or
b) identifying the subject as having secondary progressive multiple sclerosis based on the protein expression levels of the at least 6 proteins, and treating the subject identified as having secondary progressive multiple sclerosis with one or more therapies selected from stem cell therapy, steroids, beta interferon, glatiramer acetate, cladribine, dimethyl fumarate, and Siponimod.

### Claim 64 (depends on 53)

The method of claim 53, wherein the subject is a human.
